Free Trial

Check-Cap Q3 2023 Earnings Report

Check-Cap logo
$0.76 -0.01 (-1.47%)
As of 02/21/2025 03:46 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Check-Cap EPS Results

Actual EPS
-$0.44
Consensus EPS
-$0.83
Beat/Miss
Beat by +$0.39
One Year Ago EPS
N/A

Check-Cap Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Check-Cap Announcement Details

Quarter
Q3 2023
Time
Q3 2023 Earnings Release

Conference Call Resources

Check-Cap Earnings Headlines

$5,000 DOGE check?
Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a portion of the savings DOGE makes in Federal cuts could be funneled back to taxpayers. The media was quick to dub it a DOGE Dividend, with claims circulating that we could all receive a $5,000 check in the mail.
See More Check-Cap Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Check-Cap? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Check-Cap and other key companies, straight to your email.

About Check-Cap

Check-Cap (NASDAQ:CHEK), a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.

View Check-Cap Profile

More Earnings Resources from MarketBeat